http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112569338-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d90550430154fb12a68681262b676215 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate | 2020-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6564c77532ce139a0121481287c6a53d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5e582564907e7318b78147068712033 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a570eda05d6ebb54203b08dba5457e7d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c27b8072e95a95918cb57525a85ae1e |
| publicationDate | 2021-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112569338-A |
| titleOfInvention | Application of TDFA in the preparation of medicaments for preventing and/or treating ocular surface inflammatory diseases |
| abstract | The invention relates to the technical field of medicine, in particular to the application of TDFA in the preparation of medicines for preventing and/or treating ocular surface inflammatory diseases. This application provides an important supplement to the current mechanism research and drug targets of ocular surface inflammatory diseases, and broadens the research and application fields of TFAD. Compared with traditional anti-inflammatory drugs for ocular surface inflammatory diseases, TDFA targets NETs At the same time, it can be administered non-invasively by using local instillation in the eye area, exerting its effect through local penetration, and forming a higher drug concentration locally, which can easily obtain better drug efficacy, and significantly improve the drug in the systemic circulation. content, reduces its potential systemic side effects, and has a higher safety profile. |
| priorityDate | 2020-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 271.